|
Match
|
Document |
Document Title |
|
|
7510830 |
Cancer treatment by combination therapy
Methods and compositions are provided for treating cancer, the methods including the step administering, either sequentially or simultaneously, (i) a compound of the xanthenone acetic acid group of...
|
|
|
7504485 |
Human antibodies that bind human IL-12
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize...
|
|
|
7501247 |
Method of treating skin inflammation
Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17 and/or IL-23.
|
|
|
7494647 |
Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
A humanized antibody against tissue factor (TF), comprising: A: a humanized H chain comprising (1) a H chain V region comprising the H chain CDRs of a mouse monoclonal antibody against TF and the...
|
|
|
7494651 |
TGF-β binding antibodies
The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are...
|
|
|
7491389 |
Modulating angiogenesis
Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can...
|
|
|
7491516 |
Dual specificity antibodies and methods of making and using
Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or...
|
|
|
7482004 |
Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF −/− ) that does not...
|
|
|
7482005 |
Methods of treating diseases with anti-VEGF antibodies
The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related...
|
|
|
7479271 |
Humanized anti-ghrelin antibodies
Humanized antibodies, or antigen-binding portions thereof, that preferentially bind acylated ghrelin with respect to unacylated ghrelin, are disclosed. These molecules have high affinity and a slow...
|
|
|
7468184 |
Therapeutic agent for cachexia
The invention relates to a therapeutic agent for cachexia comprising, as an active ingredient, a substance capable of inhibiting the binding between a parathyroid hormone related protein (PTHrP)...
|
|
|
7449616 |
Anti-NGF antibodies and methods using same
The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or...
|
|
|
7445778 |
Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor
A method for inhibiting growth or differentiation of an epithelial cell comprising contacting at least an epithelial cell with an effective amount of an agent selected from the group consisting of...
|
|
|
7446180 |
Conformationally abnormal forms of tau proteins and specific antibodies thereto
Invention relates to antibodies with a specificity to an abnormally truncated form of tau protein which is conformationally different from normal tau and does not bind to normal tau protein,...
|
|
|
7445779 |
Methods of modulating IFNy production
Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists and antagonists. Also provided are methods of treatment of immune and proliferative disorders.
|
|
|
7438911 |
Antibody against human insulin-like growth factor
For the effective treatment of diseases such as cancer in which hIGF participates, there have been desired to be developed antibodies which strongly bind to both factors hIGF-I and hIGF-II and...
|
|
|
7438908 |
Anti-human tenascin monoclonal antibody
A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the...
|
|
|
7435413 |
Anti-tissue factor antibodies with enhanced anticoagulant potency
The invention concerns anti-tissue factor (anti-TF) antibodies with enhanced anticoagulant potency, and methods and means for identifying, producing and using such antibodies. The anti-TF...
|
|
|
7431927 |
TNFα-neutralizing antibodies
The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from...
|
|
|
7431924 |
Methods of treating inflammation using mammalian CX3C chemokine antibodies
Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using...
|
|
|
7427402 |
Method of evaluating inflammatory skin disorders using IL-17 and/or IL-19
Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19,...
|
|
|
7427403 |
Methods for inhibiting lymphotoxin β receptor signalling
This invention relates to compositions and methods comprising “lymphotoxin-β receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents...
|
|
|
7425330 |
Methods of inhibiting TNFα activity in the blood of a patient
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7425329 |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth...
|
|
|
7422743 |
Mammalian receptor protein DCRS5;methods of treatment
Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the...
|
|
|
7422742 |
Methods for using human monoclonal antibodies to interleukin-5
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human...
|
|
|
7416729 |
Methods of treating rheumatoid arthritis with anti-TNF antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7410639 |
Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use
VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as...
|
|
|
7410641 |
Antibodies to insulin/IGF/relaxin family polypeptides
The present invention relates to antibodies that bind to the A chain N-terminal peptide. The present invention also relates to (1) a polypeptide containing the same or substantially the same amino...
|
|
|
7411050 |
Monoclonal blocking antibody to human RANKL
Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL.
|
|
|
7404955 |
Methods of inhibiting or neutralizing TNFα in patients with tissue injury
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7402578 |
Methods for inhibiting cognitive deterioration in adults with down's syndrome
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can...
|
|
|
7402662 |
Antibody molecules specific to human tumor necrosis factor alpha
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein...
|
|
|
7402312 |
Antibodies to vascular endothelial growth factor 2 (VEGF-2)
Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention also relates to methods and...
|
|
|
7402313 |
Method for controlling preeclampsia and eclampsia
A method of controlling preeclampsia includes the steps of providing a supply of digoxin immune Fab (ovine), calculating an appropriate dosage of the digoxin immune Fab (ovine) based on a patient's...
|
|
|
7390491 |
Agents comprising midkine or an inhibitor thereof as active ingredient
Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its...
|
|
|
7384634 |
Connective tissue growth factor
The present invention provides a novel polypeptide, Connective Tissue Growth Factor (CTGF), polynucleotides encoding CTGF and polynucleotides regulating CTGF expression. The invention also provides...
|
|
|
7371384 |
Compositions and methods of using angiopoietin-like 4 protein antibody
ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to...
|
|
|
7371383 |
Recombinant anti-interleukin-9 antibodies
The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat...
|
|
|
7368111 |
Human antibodies specific for TGFβ2
Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both,...
|
|
|
7364735 |
Method for diagnosis and treatment of haemophilia A patients with an inhibitor
A polynucleotide, comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity, or complementary to a nucleotide sequence coding for a human antibody for...
|
|
|
7364732 |
Method for treating inflammation
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its...
|
|
|
7364736 |
Antibodies to OPGL
Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are...
|
|
|
7361339 |
Methods for reducing morality associated with acute myocardial infarction
Methods of reducing mortality in myocardial infarction patients receiving a stent in connection with percutaneous transluminal coronary angioplasty include administering an anti-inflammatory...
|
|
|
7354584 |
Recombinant IL-9 antibodies
The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and...
|
|
|
7354585 |
Methods of treating coagulapathic or thrombotic disorders
The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention...
|
|
|
7348002 |
Inducible ligand for α1β1 integrin and uses
The present invention is directed to the identification and use of agents, particularly peptides and monoclonal antibodies that disrupt the interaction between Collagen XIII and α1β1 integrin.
|
|
|
7344716 |
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.
|
|
|
7342110 |
Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced...
|
|
|
7329737 |
Antibodies that bind hK-1
The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.
|